What's better than momentum? Mo' momentum.

Let's take a closer look at five of this past week's biggest scorchers.

Company

July 13 Weekly Gain My Watchlist
Amerigroup (NYSE: AGP) $89.95 40% Add
Affymax (Nasdaq: AFFY) $16.49 30% Add
Orexigen Therapeutics (Nasdaq: OREX) $7.06 22% Add
Complete Genomics (Nasdaq: GNOM) $2.44 18% Add
SkyWest (Nasdaq: SKYW) $7.96 14% Add

Source: Barron's.

Amerigroup was the picture of health, soaring nearly 40% after WellPoint struck a deal to acquire the Medicaid coverage specialist. The all-cash deal will take Amerigroup shareholders out at $92, a healthy premium to where the stock was just before the deal was announced.

Affymax was one of the market's biggest winners after a company announced that it would be rolling out Affymax's anemia drug Omontys -- a drug that boosts red blood cell production for dialysis patients -- in at least 100 dialysis centers.

Orexigen shares fattened up after the company reported strong enrollment for its diet-drug study. The heavy demand now finds Orexigen targeting interim analysis of the study concluding by early next year, a lot earlier than original expectations.

Complete Genomics was DNA -- as in Deserving Notable Appreciation -- after introducing a new technology that can potentially set the new standard for clinical-grade genomes.

Regional air carrier SkyWest took off after placing an order with Mitsubishi for 100 jets.

More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.